Character Bio applies genomics, multi-modal data integration, and machine learning to drug development for progressive, polygenic diseases, with a current focus on ophthalmology. Founded in 2019, the company operates from headquarters in Jersey City, New Jersey, with additional operations in San Francisco, California.
The company has built a platform combining genetic, clinical, and imaging data across over 150 ophthalmology clinic partnerships. This data infrastructure is designed to reclassify complex diseases like age-related macular degeneration (AMD) into genetically defined subtypes, enabling the identification of novel therapeutic targets and optimisation of patient selection for clinical trials.
Character Bio's lead development programmes, CTX114 and CTX203, are both advancing toward clinical trials in AMD. The company has raised over $110 million in Series B funding from investors including aMoon, Luma Group, Bausch + Lomb, Innovation Endeavors, and Sanofi Ventures. It was named a Fierce 15 Biotech Company of 2025 by Fierce Biotech.
